Table 2.

Summary of effects of ACE-Is in mouse models of AD including Aβ levels and deposition, neuroinflammation and oxidative stress and, cognitive deficits.

Mouse model	Drug (*brain penetrant)	Treatment duration and Age	Administration route	Dose	Results	Reference
Tg2576 mice (APPSwedish)	Captopril*	11 months, starting at 6 months old	Oral administration	30 mg/kg/d	↑Aβ levels and plaques	Zou et al. (2007)
Tg2576 mice (APPSwedish)	Captopril*	11 months, starting at 6 months old	Oral administration	30 mg/kg/d	↑Aβ levels and plaques	Liu et al. (2019)
3xTg-AD mice (APPSwedish/PSEN1M146V/TauP301L) J20 mice (APPSwedish/Indiana)	Captopril*	1 months, starting at 16 months old	Drinking water	2 g/l	No effect on Aβ levels and plaques	Hemming et al. (2007)
PS2APP Tg mice (APPSwedish/PSEN2N141I)	Perindopril*	1 months, starting at 3 months old	Oral administration	1 mg/kg/d	↑ Memory; No effect on Aβ levels; ↓ Inflammation	Dong et al. (2011)
Tg2576 mice (APPSwedish)	Captopril*	6 months, starting at 12 months old	Drinking water	20 mg/kg/d or 25 mg/kg/d	↓ Aβ plaques; ↓ oxidative stress	AbdAlla et al. (2013)
5XFAD Tg mice (APPSwedish/Florida/London /PSEN1M146L, L286V)	Captopril*	2 months, starting at 8 weeks old	Intranasal administration	5 mg/kg/d	↓ Aβ plaques; ↓ Inflammation	Asraf et al. (2018)
5XFAD Tg mice (APPSwedish/Florida/London /PSEN1M146L, L286V)	Captopril*	3.5 weeks, starting at 3 months old	Intranasal administration	5 mg/kg/d	No effect on Aβ plaques; ↓ Inflammation	Torika et al. (2016)
5XFAD Tg mice (APPSwedish/Florida/London /PSEN1M146L, L286V)	Perindopril*	3.5 weeks, starting at 3 months old	Intranasal administration	1 mg/kg/d	↓ Aβ plaques; ↓ Inflammation	Torika et al. (2016)
5XFAD Tg mice (APPSwedish/Florida/London /PSEN1M146L, L286V)	Captopril*	7 months, starting at 2 months old	Intranasal administration	5 mg/kg/d	↓ Aβ plaques	Torika et al. (2016)

Drugs marked with (*) indicate BBB penetrance.